Third Harmonic Bio, Inc. (THRD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

The heavy selling pressure might have exhausted for Third Harmonic Bio, Inc. (THRD) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall ...

What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Friday showed that BenNatan purchased 7,780 shares of Harmonic. The total transaction amounted to $75,060. Harmonic ...

Harmonic Inc. (NASDAQ:HLIT – Get Free Report) reached a new 52-week low during trading on Tuesday after Rosenblatt Securities ...

Third Harmonic Bio plans a Phase 2 trial for THB335 in chronic spontaneous urticaria and will reduce its workforce by 50% ...

Harmonic (NASDAQ:HLIT – Get Free Report) declared that its board has initiated a stock repurchase plan on Monday, February ...

Third Harmonic Bio shares dived 35% in premarket trading amid a broader evaluation of THB335. Shares were trading around $3.03. The stock is down 50% over the last year.

Q4 2024 Earnings Call Transcript February 10, 2025 Harmonic Inc. beats earnings expectations. Reported EPS is $0.45, expectations were $0.37. Operator: Welcome to the Fourth Quarter and Full Year 2024 ...

Needham analysts adjusted their outlook on Harmonic Inc . (NASDAQ:HLIT), lowering the price target to $14 from $18 while ...

THB335 Phase 1 data support advancement into Phase 2 clinical trial in chronic spontaneous urticaria (CSU)Company initiating process to leverage ...

The MAD cohort also saw adverse events such as hair loss and reductions in hemoglobin and neutrophil counts. These side ...